Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma

Naka, Takahiko; Kuester, Doerthe; Boltze, Carsten; Schulz, T.; Samii, Amir; Herold, Christian; Ostertag, Helmut; Roessner, Albert

doi:10.1016/j.humpath.2007.06.005

Cited by 31 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] In a previous study of Naka et al, MMP-1 and MMP-2 were frequently expressed in a small series of non-skull base chordomas. [15] In glioma, MMP-9 expression was thought to be regulated by inflammatory cytokines such as tumor necrosis factor α and interleukins.…”

Section: -Year-old Man Was Admitted To Ear Nose and Throat (Entmentioning

confidence: 93%

“…[9,10,11,13,15,16,18,19] There are only two studies found concerning MMPs in chordomas. [15,16] A major function of MMPs in metastasis is to facilitate the breakdown of the extracellular matrix, including the basement membrane, and they also play a substantial role in the maintenance of a microenvirontment that facilitates the growth and angiogenesis of a tumor. MMPs degrade various types of collagen, especially type IV collagen which is a chief constituent of the basement membrane of 3 brain vessels.…”

Section: Introductionmentioning

confidence: 99%

“…[9,10,11] Recent studies have indicated that expression of MMPs correlates with invasiveness of certain brain tumors. [9,10,11,13,15,16,18,19] In the present study, we examined MMP-2 and MMP-9 expression immunohistochemically in initial and recurrent surgeries of skull base chordomas. We also examined the role of RECK (reversion-inducing cysteine-rich protein with Kazal motifs), a membrane-anchored regulator of matrix metalloproteinase which is widely expressed in healthy tissues, whereas it is expressed at lower levels in many tumor-derived cell lines.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas

et al. 2009

View full text Add to dashboard Cite

Prognosis of chordomas is difficult to predict based solely on histological findings. The purpose of this study was to assess expressions of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and matrix metalloproteinase (MMP)-2, MMP-9 in skull base chordomas and to find out their correlations to outcome.Immunohistochemical study was performed in 19 samples (initial, n=11; recurrent, n=8) from 11 patients. The correlations among expression of RECK, MMP-2, MMP-9 and their prognostic values were analyzed. Significant correlation between RECK and MMP-9 was found, but there was no correlation found between MMP-2 and MMP-9.Higher MMP-9 expression significantly influenced outcome. Furthermore, MMP-9/RECK ratio showed significant correlation to outcome, showing their inverse relationship in the disease progress of skull base chordoma. RECK and MMP-9 can be valuable markers to predict prognosis in skull base chordomas.

show abstract

Section: -Year-old Man Was Admitted To Ear Nose and Throat (Entmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The present study and that by Chen et al found no association between VEGF expression and disease-free survival or the survival rate; however, the number of patients in the two studies may not be sufficient to obtain prognostic information. Naka et al found that in skull base chordoma, MMP-9 was rarely expressed, but MMP-2 expression was frequently observed (27). These authors also found that MMP-2 expression was of prognostic value in non-skull base chordoma, but not in skull base chordoma (27,28).…”

Section: A B C a B C D Discussionmentioning

confidence: 95%

“…Naka et al found that in skull base chordoma, MMP-9 was rarely expressed, but MMP-2 expression was frequently observed (27). These authors also found that MMP-2 expression was of prognostic value in non-skull base chordoma, but not in skull base chordoma (27,28). Although different results were observed in the skull base and non-skull base chordomas, together, these data indicate that the expression of VEGF and MMPs may be significant in chordoma progression.…”

Section: A B C a B C D Discussionmentioning

confidence: 99%

Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Hypoxia-inducible factor-1α (HIF-1α) has been reported to transactivate the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2), which are frequently overexpressed in numerous types of cancer and are known to be significant regulators of angiogenesis. Few studies have investigated the role of these factors in solid tumors, particularly chordomas, which are rare tumors that are thought to originate from notochordal remnants. To clarify whether HIF-1α is involved in angiogenesis in chordoma tissues, we examined the expression of HIF-1α, VEGF and MMP-2 with immunohistochemistry using a tissue microarray containing 35 chordoma samples. The results indicated that HIF-1α, VEGF and MMP-2 are expressed in the majority of chordoma samples. VEGF expression was significantly correlated with HIF-1α and MMP-2 expression, as well as with microvessel density (MVD). However, the prognosis of the chordoma patients was not significantly associated with the expression of these factors, but was associated with MVD. The results therefore showed that there is a correlation between the expression of HIF-1α, VEGF and MMP-2 in chordomas and that the angiogenic process is a potential therapeutic target for chordomas.

show abstract

Expression of hepatocyte growth factor and c‐MET in skull base chordoma

Naka

Kuester

Boltze

et al. 2007

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND. Hepatocyte growth factor (HGF) is a multipotent cytokine that is mediated by its receptor, c‐MET. HGF/c‐MET contributes to tumor progression in many human malignancies; however, HGF/c‐MET is inversely correlated with aggressive biologic behavior in other cancers. Conversely, to the authors' knowledge, little is known regarding the significance of HGF/c‐MET expression in skull base chordoma. METHODS. Using immunohistochemical techniques, the authors investigated HGF/c‐MET expression in 46 primary and 25 recurrent lesions, and compared it with the expression of proteinases and cell differentiation markers, proliferative ability, and other clinicopathologic parameters. RESULTS. c‐MET was found to be expressed in 70.0% of primary and 88.0% of recurrent lesions. HGF expression was scarcely detected. Higher c‐MET expression was found to be correlated with younger patient age. Lesions with a higher expression of low molecular weight cytokeratin (CAM5.2) demonstrated significantly higher c‐MET scores in both primary and recurrent lesions compared with those with lower CAM5.2 expression. In recurrent lesions, higher c‐MET expression was found to be associated with the scores of matrix metalloproteinase (MMP)‐1, MMP‐2, tissue inhibitor of matrix metalloproteinase‐1, and urokinase plasminogen activator (uPA); however, only uPA was found to be correlated with higher c‐MET expression in primary lesions. c‐MET expression did not appear to be correlated with MIB‐1 labeling index. Patients with higher c‐MET expression were found to have longer survival. CONCLUSIONS. In the current study, c‐MET expression was a common event, and was found to be correlated with CAM5.2 expression, younger patient age, and a favorable prognosis in patients with skull base chordoma. However, HGF/c‐MET paracrine signaling also may contribute to its invasive ability, especially in recurrent lesions. Cancer 2008. © 2007 American Cancer Society.

show abstract

Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma

Cited by 31 publications

References 27 publications

Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas

Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas

Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas

Expression of hepatocyte growth factor and c‐MET in skull base chordoma

Contact Info

Product

Resources

About